Renaissance Technologies LLC Sells 214,252 Shares of OptiNose, Inc. (NASDAQ:OPTN)

Renaissance Technologies LLC lessened its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 94.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,748 shares of the company's stock after selling 214,252 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of OptiNose worth $85,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC lifted its holdings in OptiNose by 33.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company's stock valued at $870,000 after purchasing an additional 326,918 shares during the last quarter. Institutional investors and hedge funds own 85.60% of the company's stock.

Insider Transactions at OptiNose

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 8,213 shares of company stock worth $43,643. Company insiders own 2.30% of the company's stock.

Analysts Set New Price Targets

OPTN has been the subject of a number of research analyst reports. HC Wainwright restated a "neutral" rating and set a $9.00 price objective (down previously from $18.00) on shares of OptiNose in a report on Friday, March 21st. Piper Sandler reiterated a "neutral" rating and set a $9.00 price objective (down previously from $15.00) on shares of OptiNose in a research report on Friday, March 21st. Finally, Lake Street Capital cut shares of OptiNose from a "buy" rating to a "hold" rating and reduced their target price for the company from $17.00 to $9.00 in a research report on Thursday, March 20th.

OptiNose Price Performance

Shares of NASDAQ:OPTN remained flat at $9.39 during midday trading on Friday. The stock had a trading volume of 8,064 shares, compared to its average volume of 59,589. OptiNose, Inc. has a 52 week low of $4.82 and a 52 week high of $20.03. The business's 50 day simple moving average is $8.39 and its 200-day simple moving average is $7.50. The firm has a market cap of $95.09 million, a PE ratio of -2.24 and a beta of -0.88.

OptiNose (NASDAQ:OPTN - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.67. The company had revenue of $21.47 million during the quarter, compared to the consensus estimate of $21.02 million. Research analysts forecast that OptiNose, Inc. will post -3.22 earnings per share for the current fiscal year.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.